Subscribe To
XENE / Xenon Pharmaceuticals: Navigating The Neural Network Of Epilepsy And Depression
Content Topics
Xenon
Pharmaceuticals
Navigating
Neural
Network
Epilepsy
Pharmaceuticals
Depression
Stock
XENE
XENE News
By GlobeNewsWire
November 1, 2023
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company more_horizontal
By GlobeNewsWire
September 14, 2023
Xenon Pharmaceuticals to Present at TD Cowen's 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical compan more_horizontal
By GlobeNewsWire
August 31, 2023
Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference
VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company more_horizontal
By Seeking Alpha
August 13, 2023
Xenon Is Well-Funded Heading Into Key Readouts
Xenon Pharmaceuticals has a strong cash position of $652.2M and an estimated cash runway of approximately 3.11 years. The company's financial health i more_horizontal
By Zacks Investment Research
August 11, 2023
Wall Street Analysts Believe Xenon Pharmaceuticals (XENE) Could Rally 36.75%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in Xenon Pharmaceuticals (XENE). While the effectivenes more_horizontal
By Seeking Alpha
August 9, 2023
Xenon Pharmaceuticals Inc. (XENE) Q2 2023 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Morti more_horizontal
By Zacks Investment Research
August 9, 2023
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
Xenon Pharmaceuticals (XENE) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares t more_horizontal
By GlobeNewsWire
June 6, 2023
Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company more_horizontal
